| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 01/18/2000 | CA2087960C Endogenously sweetened transgenic plant products |
| 01/18/2000 | CA2050336C Yeast processing system comprising a negatively charged amino acid adjacent to the processing site |
| 01/18/2000 | CA2013239C Yeast strains for the production of nature heterolegous proteins, especially hirudine, and corresponding process for the preparation of hirudine |
| 01/18/2000 | CA2012895C Recombinant cytomegalovirus vaccine |
| 01/18/2000 | CA2006587C Membrane proteins and peptides of haemophilus influenzae type b |
| 01/18/2000 | CA1340877C Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology |
| 01/18/2000 | CA1340876C The vp7 gene of human rotavirus 4 |
| 01/18/2000 | CA1340875C Variants of lav viruses their dna- and protein- components and their uses, particularly for diagnostic purposes and for the preparation of immunogenic compositions |
| 01/14/2000 | CA2237704A1 Cleavage of caulobacter produced recombinant fusion proteins |
| 01/13/2000 | WO2000001837A1 (-)-strand rna virus vector for nerve cell |
| 01/13/2000 | WO2000001834A1 Recombinant herpes viruses for preparing recombinant adeno-associated viruses |
| 01/13/2000 | WO2000001832A2 Inducible promoters |
| 01/13/2000 | WO2000001831A2 Proteases fused with variants of streptomyces subtilisin inhibitor |
| 01/13/2000 | WO2000001830A1 Promoters and promoter elements for increasing the pathogen inducibility of genes in plants |
| 01/13/2000 | WO2000001826A2 Stabilized variants of streptomyces subtilisin inhibitor |
| 01/13/2000 | WO2000001824A2 Method for genetic engineering of disease resistance using the drr206 class of proteins |
| 01/13/2000 | WO2000001823A2 Flt3-l mutants and methods of use |
| 01/13/2000 | WO2000001821A2 Neurotransmission associated proteins |
| 01/13/2000 | WO2000001820A2 Nucleic acid molecules encoding nuclear hormone receptor coactivators, and uses thereof |
| 01/13/2000 | WO2000001819A1 Human elk, a voltage-gated potassium channel subunit |
| 01/13/2000 | WO2000001818A1 Human emr1-like g protein coupled receptor |
| 01/13/2000 | WO2000001817A2 Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12), md-1, md2 and cyclin e2, related reagents and methods |
| 01/13/2000 | WO2000001816A1 TUMOUR SUPPRESSOR GENE DBCCR1 AT 9q32-33 |
| 01/13/2000 | WO2000001815A2 Neurotrophic factors |
| 01/13/2000 | WO2000001814A2 Non-human mammal wherein a gene coding for an scuz-protein can be de-activated in a time-specific or tissue-specific manner |
| 01/13/2000 | WO2000001813A2 Peptide inhibitors of androgen-independent activation of androgen receptor |
| 01/13/2000 | WO2000001811A1 Kv6.2, A VOLTAGE-GATED POTASSIUM CHANNEL SUBUNIT |
| 01/13/2000 | WO2000001801A1 Ftsz multimeric proteins and their uses |
| 01/13/2000 | WO2000001732A2 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| 01/13/2000 | WO2000001731A1 Fused protein with direct bond of il-6-receptor to il-6 |
| 01/13/2000 | WO2000001730A1 Peptides based on the sequence of human lactoferrin and their use |
| 01/13/2000 | WO2000001729A2 Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome |
| 01/13/2000 | WO2000001728A1 Galectin 11 |
| 01/13/2000 | WO2000001727A1 Seeding crystals for the preparation of peptides or proteins |
| 01/13/2000 | WO2000001726A1 Compounds with growth hormone releasing properties |
| 01/13/2000 | WO2000001725A1 Saccharide transporter |
| 01/13/2000 | WO2000001724A1 Microsporidium polar tube proteins, nucleic acids coding for said proteins and their uses |
| 01/13/2000 | WO2000001722A1 Manipulation of mlo genes to enhance disease resistance in plants |
| 01/13/2000 | WO2000001721A1 Methods and compositions to enhance disease resistance in plants by expression of mlo3 from maize |
| 01/13/2000 | WO2000001720A2 Compositions and methods for treating papillomavirus-infected cells |
| 01/13/2000 | WO2000001719A2 Peptides from varicella-zoster and other viruses for hiv-2 diagnosis and therapy |
| 01/13/2000 | WO2000001718A2 Ns4a-ns3 catalytic domain of hepatitis c |
| 01/13/2000 | WO2000001717A2 A method of identifying hormone receptor ligands |
| 01/13/2000 | WO2000001712A2 Chemically modified proteins with a carbohydrate moiety |
| 01/13/2000 | WO2000001440A2 Methods for treating neurological injuries and disorders |
| 01/13/2000 | WO2000001410A1 Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis |
| 01/13/2000 | WO2000001409A2 Porcine circovirus and parvovirus vaccine |
| 01/13/2000 | WO2000001408A2 Haemophilus parasuis vaccine and diagnostic |
| 01/13/2000 | WO2000001407A1 Pharmaceutical composition comprising human apotransferrin and process for manufacturing of the composition |
| 01/13/2000 | WO2000001405A1 Cartilage cell differentiation promoters |
| 01/13/2000 | WO2000001401A1 Compositions and methods for inhibiting inward-rectifier potassium channels |
| 01/13/2000 | WO2000001223A1 LECTINS TO CONFER RESISTANCE TO INSECTS IN $i(BRASSICA) |
| 01/13/2000 | WO1999060148A3 Display of viral proteins as ligands for cell-surface receptor |
| 01/13/2000 | WO1999060135A8 Generation of multiple gene products from chimeric fusion proteins by cleavage with ubiquitous endoproteases |
| 01/13/2000 | WO1999060125A3 Secreted proteins |
| 01/13/2000 | WO1999059617A3 Immunoregulator |
| 01/13/2000 | WO1999057241A3 Myelin basic protein peptides and uses thereof |
| 01/13/2000 | WO1999053953A3 Methods and products related to metabolic interactions in disease |
| 01/13/2000 | WO1999053060A3 Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
| 01/13/2000 | WO1999053047A3 Porcine adenovirus type 3 genome |
| 01/13/2000 | WO1999052936A3 Arginine peptide analogs useful as fibroblast growth factor antagonists |
| 01/13/2000 | WO1999051636A9 Gaba b receptor |
| 01/13/2000 | WO1999046367A8 Methods of diagnosis and triage using cell activation measures |
| 01/13/2000 | WO1999046286A3 Assays and reagents for identifying anti-fungal agents, and uses related thereto |
| 01/13/2000 | WO1999043709A3 Melanocortin receptor antagonists and modulations of melanocortin receptor activity |
| 01/13/2000 | WO1999037774A3 Differentiation-associated sequences and methods of use therefor |
| 01/13/2000 | WO1999018909A3 Interferon-gamma regulatory factors |
| 01/13/2000 | DE19831061A1 Reducing aggregate content of protein preparation, especially virus-inactivated therapeutic plasma protein or chemically modified protein preparation |
| 01/13/2000 | DE19830874A1 Verfahren zur Stabilisierung und Verbesserung des Gentransfers von genetischem Material in Säugerzellen A process for the stabilization and improvement of the gene transfer of genetic material into mammalian cells |
| 01/13/2000 | DE19830141A1 Rekombinante Herpesviren für die Erzeugung rekombinanter Adeno-Assoziierter-Viren Recombinant herpes viruses for the production of recombinant adeno-associated virus |
| 01/13/2000 | DE19822985C1 Tumorsuppressorgene der p53-Familie Tumor suppressor p53 family |
| 01/13/2000 | CA2402839A1 Galectin 11 |
| 01/13/2000 | CA2336718A1 Methods for treating neurological injuries and disorders |
| 01/13/2000 | CA2336406A1 Galectin 11 |
| 01/13/2000 | CA2336320A1 Haemophilus parasuis vaccine and diagnostic |
| 01/13/2000 | CA2336112A1 Seeding crystals for the preparation of peptides or proteins |
| 01/13/2000 | CA2333919A1 Microsporidium polar tube proteins, nucleic acids coding for said proteins and their uses |
| 01/13/2000 | CA2332698A1 Sugar transporter |
| 01/13/2000 | CA2332573A1 Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12), md-1, md2 and cyclin e2, related reagents and methods |
| 01/13/2000 | CA2332564A1 Stabilized variants of streptomyces subtilisin inhibitor |
| 01/13/2000 | CA2332345A1 Flt3-l mutants and methods of use |
| 01/13/2000 | CA2332309A1 Neurotransmission associated proteins |
| 01/13/2000 | CA2332177A1 Proteases fused with variants of streptomyces subtilisin inhibitor |
| 01/13/2000 | CA2331829A1 Kv6.2, a voltage-gated potassium channel subunit |
| 01/13/2000 | CA2331774A1 Inducible promoters |
| 01/13/2000 | CA2331771A1 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors |
| 01/13/2000 | CA2331394A1 Human emr1-like g protein coupled receptor |
| 01/13/2000 | CA2302169A1 Inhibitors of androgen-independent activation of androgen receptor |
| 01/12/2000 | EP0971033A2 Test and model for Alzheimer's disease |
| 01/12/2000 | EP0971032A1 Growth promoting material for useful microorganisms and process for producing the same |
| 01/12/2000 | EP0970966A1 Fungal antigens and process for producing the same |
| 01/12/2000 | EP0970965A1 Cyclic peptides and medicinal use thereof |
| 01/12/2000 | EP0970377A1 Diagnosis of epithelial cell abnormalities |
| 01/12/2000 | EP0970372A1 Assay for disease related conformation of a protein |
| 01/12/2000 | EP0970247A1 Detection of dna damaging agents |
| 01/12/2000 | EP0970232A2 Non-immunogenic prodrugs and selectable markers for use in gene therapy |
| 01/12/2000 | EP0970220A1 Method for producing non-infectious recombinant picornavirus particles |
| 01/12/2000 | EP0970219A1 A porin gene from campylobacter jejuni, related products and uses thereof |
| 01/12/2000 | EP0970218A1 Variants of vascular endothelial cell growth factor having altered pharmacological properties, and related aspects thereof |
| 01/12/2000 | EP0970216A1 TRANSGENIC MICE EXPRESSING THE $i(H/K-RAS 4B) CHIMERIC GENE |